Emily Pearson, a 25-year-old woman, has undergone a remarkable transformation after years of suffering due to a rare skin disorder known as erythropoietic protoporphyria (EPP). This condition, which effectively makes her allergic to sunlight, first manifested when she was just eight years old. Pearson’s experience with severe pain has significantly changed following her participation in a groundbreaking clinical trial for a new treatment.
:max_bytes(150000):strip_icc():format(jpeg)/woman-in-sunlight-2-100926-f701b4d900914c1792c22926ec35ebab.jpg)
At the age of eight, Emily began to experience debilitating symptoms whenever she was exposed to sunlight. Just a few minutes in the sun would lead to excruciating pain in her hands and feet, a sensation she described as akin to having them in a ‘hot oven’ while being pricked with ‘pins and needles.’ This agony could linger for days, and it was a reality she had to endure throughout her childhood and adolescence.
Her parents, desperate to find answers, sought medical help, but it wasn’t until she turned 17 that a diagnosis was finally made at the Mayo Clinic in Rochester, Minnesota. Emily was diagnosed with EPP, a condition caused by a genetic mutation that results in an excessive build-up of protoporphyrin IX—an organic compound that can lead to painful reactions upon sun exposure. The diagnosis brought some relief, but the consequences of her condition continued to dictate her life, forcing her to wear protective clothing and limit time spent outdoors.
The daily challenge of managing her condition took a significant mental toll. “Going to the grocery store or filling up the car became an exercise in constant vigilance,” she recalled. Emily’s life was dominated by the anxiety of planning every outing around her health needs, which was both exhausting and stressful.
In 2025, Pearson’s journey took a hopeful turn when she volunteered at Sun Escape, a camp designed for children with conditions like EPP. It was during this time that she learned about a clinical trial for a new medication called bitopertin. Despite her initial scepticism about the treatment, which seemed promising for others, she decided to participate in the trial after consulting with medical professionals who reassured her about the potential benefits.
Dr Sioban Keel, a porphyria specialist at the University of Washington and a key player in the clinical trial, described how bitopertin operates. The drug is administered as a once-daily pill and functions by reducing levels of protoporphyrin IX in the skin, thereby alleviating the severe reactions to sunlight experienced by patients with EPP. Following the commencement of her trial participation in July 2025, Emily began to notice significant improvements in her condition within weeks, which allowed her to gradually increase her sun exposure.
Dr Keel hailed the drug as a ‘game-changer,’ highlighting that many patients who previously could not venture outside in sunlight are experiencing newfound freedom. Currently, bitopertin is in phase three of clinical trials, with over 180 participants involved. According to the developers, Disc Medicine, results are anticipated by late 2026, with an application for FDA approval expected by mid-2027.
Pearson’s life has been transformed from one of limitation to newfound possibilities. Since beginning the medication, she has participated in her first marathon and enjoyed outdoor activities without the need for protective layers. “I was outside the whole day, running and having fun,” she said with enthusiasm. This joyous experience was a significant milestone, marking a departure from years of anxiety linked to sun exposure.
Additionally, Emily recently enjoyed a weeklong holiday at her family’s cabin in Minnesota, embracing outdoor activities from sunrise to sunset without experiencing any adverse reactions. She expressed her disbelief at how much her life has improved, describing the experience as “unimaginable.”
Reflecting on her journey, Pearson feels a sense of liberation that she had long thought unattainable. “I can now live without the worry and anxiety that consumed me before,” she remarked. “My life has changed dramatically for the better.” Emily’s story is a testament to the resilience of the human spirit and the potential of innovative medical advances to change lives for the better.